Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
With
Astellas Pharma Inc
Age
65–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male with ≥ 1 diagnosis claim for prostate cancer
Have documented secondary metastasis code on or after the initial prostate cancer diagnosis
Have initiated novel hormonal therapy (abiraterone, apalutamide, or enzalutamide) within 30 days prior to the metastasis date or on or after the metastasis date. The initiation date of the earliest novel hormonal therapy will be defined as the index date.
Have a claim for androgen deprivation therapy (ADT) within 90 days prior to or within 30 days after the index date
≥65 years old 12 months prior to the index date
Continuous enrollment in Medicare Parts A, B, and D for ≥12 months prior to the index date and ≥6 months following the index date (unless death)
You may not be if
Claims indicating ≥8 weeks of continuous ADT use between 90 and 365 days prior to the index date, which may indicate castration-resistance
Received chemotherapy, novel hormonal therapy, radium-223, PARP inhibitor, immunotherapy, or surgical castration prior to the index date
Had a prior history of other cancers
Clareo Health | A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
